Swiss Medica, Inc.

Swiss Medica, Inc.

March 01, 2005 08:00 ET

Swiss Medica Announces That Rite Aid Stores Have Begun Selling Their O24 Essential Oil Pain Neutralizer



OTC Bulletin Board SYMBOL: SWME

MARCH 1, 2005 - 08:00 ET

Swiss Medica Announces That Rite Aid Stores Have Begun
Selling Their O24 Essential Oil Pain Neutralizer

TORONTO, ONTARIO--(CCNMatthews - March 1, 2005) - Swiss Medica Inc.
(OTCBB:SWME) is pleased to announce that Rite Aid drugstores have begun
selling O24 Essential Oil Pain Neutralizer with full chainwide product
distribution expected to be completed in March.

About Rite Aid Corporation

Rite Aid Corporation operates retail drugstores in the United States.
During the fiscal year ended February 28, 2004 (fiscal 2003), the
Company operated 3,382 stores located in 28 states across the country
and in the District of Columbia. According to Chain Drug Review
magazine, Rite Aid's revenues stood at $16.87 billion for FY2003.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve
chronic ailments. We increase our market share through focused
distribution strategies in multiple sales channels. Swiss Medica's
mission is to be a world leader in the commercialization of life
enhancing bioscience products that improve quality of lives. Please
visit our websites at and

Swiss Medica's flagship product, the O24™ Essential Oil Pain
Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief
solution has been used, recommended and praised for its fast-acting and
long-lasting benefits by healthcare professionals in the United States,
Canada and in Europe. O24™ is widely available throughout Canada in
leading pharmacies and natural food stores. It is currently available in
Happy Harry's Discount Drugstores in the United States, or by visiting, for ordering details and store locators.

Forward-looking statements in this news release are made pursuant to the
"Safe Harbor" provisions of the United States Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties, including,
without limitation, risks relating to the ability to close transactions
being contemplated, risks related to international sales and potential
foreign currency exchange fluctuations, continued acceptance of Swiss
Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks
detailed from time to time in Swiss Medica's periodic reports filed with
the United States Securities and Exchange Commission and other
regulatory authorities.


Contact Information

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    1 866 485 4243
    Blue Skye PR, Inc.
    Press Contact:
    Sky Wallen
    813 732 6869